Literature DB >> 7934713

Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment.

S B Cantor1.   

Abstract

The principle of extended dominance is applied in incremental cost-effectiveness analysis to eliminate from consideration strategies whose costs and benefits are improved by a mixed strategy of two other alternatives. Ethical considerations arise, however, in that equal care is not provided to all of the population. To explore these concerns, the authors establish a theoretical health care example with three diagnostic strategies. They demonstrate, both algebraically and geometrically, how to calculate the set of all possible mixed strategies that dominate the strategy eliminated by extended dominance. With the consideration of budget constraints, they define the "coefficient of inequity" as the minimum proportion of the population that would receive an inferior health care strategy if a mixed strategy were to be used instead of the dominated strategy. The implications of cost-effectiveness analysis are made explicit, revealing classic economic concerns about the tradeoff of equity and efficiency.

Mesh:

Year:  1994        PMID: 7934713     DOI: 10.1177/0272989X9401400308

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  51 in total

Review 1.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

2.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

3.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Authors:  Victor R Grann; Priya R Patel; Judith S Jacobson; Ellen Warner; Daniel F Heitjan; Maxine Ashby-Thompson; Dawn L Hershman; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-07-20       Impact factor: 4.872

4.  Visual screening for malignant melanoma: a cost-effectiveness analysis.

Authors:  Elena Losina; Rochelle P Walensky; Alan Geller; Frederick C Beddingfield; Lindsey L Wolf; Barbara A Gilchrest; Kenneth A Freedberg
Journal:  Arch Dermatol       Date:  2007-01

5.  HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.

Authors:  Rochelle P Walensky; Milton C Weinstein; Yazdan Yazdanpanah; Elena Losina; Lauren M Mercincavage; Siaka Touré; Nomita Divi; Xavier Anglaret; Sue J Goldie; Kenneth A Freedberg
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

6.  Cost-effectiveness analysis of smoking cessation interventions using cell phones in a low-income population.

Authors:  Allan T Daly; Ashish A Deshmukh; Damon J Vidrine; Alexander V Prokhorov; Summer G Frank; Patricia D Tahay; Maggie E Houchen; Scott B Cantor
Journal:  Tob Control       Date:  2018-06-09       Impact factor: 7.552

7.  Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.

Authors:  Ashish A Deshmukh; Elizabeth Y Chiao; Scott B Cantor; Elizabeth A Stier; Stephen E Goldstone; Alan G Nyitray; Timothy Wilkin; Xiaojie Wang; Jagpreet Chhatwal
Journal:  Cancer       Date:  2017-09-26       Impact factor: 6.860

8.  Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Authors:  Kostas Athanasakis; Eleftheria Karampli; Dimitrios Tsounis; Aikaterini Bilitou; John Kyriopoulos
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

9.  Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.

Authors:  Kenneth J Smith; Angela R Wateska; Mary Patricia Nowalk; Mahlon Raymund; Bruce Y Lee; Richard K Zimmerman
Journal:  Am J Prev Med       Date:  2013-04       Impact factor: 5.043

10.  The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

Authors:  Michael P Girouard; Paul E Sax; Robert A Parker; Babafemi Taiwo; Kenneth A Freedberg; Roy M Gulick; Milton C Weinstein; A David Paltiel; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.